as 12-20-2024 3:39pm EST
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Founded: | 1995 | Country: | United States |
Employees: | N/A | City: | REDWOOD CITY |
Market Cap: | 251.5M | IPO Year: | 2020 |
Target Price: | $11.92 | AVG Volume (30 days): | 252.9K |
Analyst Decision: | Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.47 | EPS Growth: | N/A |
52 Week Low/High: | $5.46 - $14.84 | Next Earning Date: | 02-19-2025 |
Revenue: | $79,302,000 | Revenue Growth: | 22.34% |
Revenue Growth (this year): | 22.26% | Revenue Growth (next year): | 18.72% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Dec 2 '24 | Sell | $6.19 | 4,376 | $27,065.16 | 291,057 | |
Lehman David Aaron | LUNG | GENERAL COUNSEL | Dec 2 '24 | Sell | $6.19 | 5,497 | $34,006.23 | 202,938 | |
French Glendon E. III | LUNG | Director | Nov 22 '24 | Sell | $6.63 | 20,000 | $132,600.00 | 1,071,974 | |
French Glendon E. III | LUNG | Director | Oct 17 '24 | Sell | $6.52 | 20,000 | $130,400.00 | 1,071,974 |
LUNG Breaking Stock News: Dive into LUNG Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Zacks
a month ago
GlobeNewswire
a month ago
Business Wire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
Zacks
2 months ago
Simply Wall St.
2 months ago
The information presented on this page, "LUNG Pulmonx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.